tbuckley/cabot-search huggingface dataset:
STMC-21. ASTROCYTOMA MUTATIONS IDH1, p53 AND ATRX COOPERATE TO BLOCK DIFFERENTIATION OF NEURAL STEM CELLS VIA Sox2
Authors: Aram Modrek, Danielle Golub, Themasap Khan, Guoan Zhang, Michael Kader, Christopher Bowman, Jod Prado, N. Sumru Bayin, Joshua Frenster, Tenzin Lhakhang, Adriana Heguy, John Dankert, Aristotelis Tsirigos, Matija Snuderl, Thomas Neubert, Dimitris Placantonakis
Journal: Neuro-Oncology (2016)

The presence of a common IDH1 mutation in two divergent tumor lineages, astrocytoma and oligodendroglioma, suggests that it is a driver mutation that occurs early in the cascade of mutations in a progenitor-like cell. To test the hypothesis that mutant IDH1 is a driver of gliomagenesis, we used human embryonic stem cell derived neural stem cells (NSCs) to overexpress mutant IDH1 protein systematically in combination with p53 and ATRX knockdown, thereby modeling the mutations found in astrocytomas. Expression of mutant IDH1 resulted in robust production of 2-hydroxyglutarate. Mutant IDH1 alone paradoxically decreased proliferative capacity, increased apoptotic rates and blocked neuronal and astrocytic differentiation. The addition of p53 knockdown reversed all of these phenotypes. The third “oncogenic hit” of ATRX knockdown reverted the phenotype to a state characterized by normal proliferation and apoptotic rates, but maintained the block in differentiation. Analysis of the transcriptome and DNA methylome revealed that thousands of genes and methylation sites were also subject to a “switching” phenotype dependent on the oncogenic mutations present. Global comparisons of these transcriptomes and methylomes revealed NSCs with IDH1 mutations more closely resembled LGGs with IDH1 mutations, while control NSCs more closely resembled wild-type IDH1 LGGs. We found that Sox2, a master stem-cell transcription factor, was strikingly down-regulated in NSCs with oncogenic mutations that were not differentiating. Preliminary evidence suggests that restoration of Sox2 expression rescues the differentiation block induced by mutant IDH1, suggesting a critical regulation of transcription factor networks by mutant IDH1 during early gliomagenesis. Our findings indicate that mutant IDH1 initiates robust and coordinated transcription factor network alterations that promote tumorigenesis by arresting differentiation of neural stem/progenitor cells.
Nonhematological Tumor Metastasis in the Bone Marrow: An Analysis of 10112 Unselected Plastic-Embedded Biopsy Sections.
Authors: Xiao Li, Ying Tao, Yizhi Liu, Luxi Song, Lingyun Wu, Shaoxu Ying, Chunkang Chang, Quan Pu
Journal: Blood (2007)
Identification of Small Molecule Modulators to Enhance the Therapeutic Properties of Chimeric Antigen Receptor T Cells
Authors: Jonathan Rosen, Betsy Rezner, David Robbins, Ian Hardy, Eigen Peralta, Christian Maine, Mohsen Sabouri, Sarah Reynal, Christopher Truong, Stacey Moreno, Heather Foster, Sarah Borchelt, Miguel Meza, Lucas Thompson, Jason Fontenot, Ryan P Larson, Mirna Mujacic, Daniel Shoemaker
Journal: Blood (2016)
Brigatinib (BRG) in Crizotinib (CRZ)-Refractory ALK+ Non–Small Cell Lung Cancer (NSCLC): efficacy and safety results from ALTA, a pivotal randomized phase 2 Trial
Authors: D. Kim, M. Tiseo, M. Ahn, K. Reckamp, K. Holmskov Hansen, S. Kim, R. Huber, H. West, H. Groen, M. Hochmair, N. Leighl, S. Gettinger, C. Langer, L. Paz-Ares Rodriguez, E. Smit, W. Reichmann, D. Kerstein, F. Haluska, D. Camidge
Journal: Annals of Oncology (2016)
Reforming Federal Public Health Powers
Authors: Lawrence O. Gostin, James G. Hodge
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
P16.04 Exploring of support needs of family caregivers for patients with primary malignant brain tumor in end of life
Authors: H. Sato, Y. Narita, Y. Miyakita, T. Majima
Journal: Neuro-Oncology (2016)

AbstractBackground:Primary malignant brain tumor is not only life threatening illness but also has neurological, physical, cognitive, behavioral, and emotional symptoms. This gives a challenging role of family caregivers. There are lots of researches which addressing these family caregivers in overseas but not in Japan. The support for family caregivers is influenced by social and cultural back ground. Therefore, to improve family caregivers’ outcome, it is essential to have own strategy as well as knowledge and implication from overseas. This study is a first step for a strategy, aimed to investigate family caregivers’ support needs during taking care of primary malignant brain tumor patients in end of life.Methods:Family caregivers, it has passed more than a half year and less than 3 years from the death of their loved one who had primary malignant brain tumor, were recruited from a neurosurgical clinic. Interviews were conducted in their home or clinic which they had chosen. Interviews were audio-recorded if they agree on it. When they did not agree to audio-recording, they allowed to make notes. The audio-recording and notes were transcribed verbatim. The data were collected by a semi-structured interview, and qualitatively analyzed with reference to the method of content analysis of Krippendorff. This study was approved by the Institution Ethics Review board. And also this study is part of the broader research, which examined how caregivers with brain tumor patients need support.Results:Interviews were conducted with 8 family caregivers (7 spouse, 1 parent). Qualitative analysis of interview transcripts identified 4 contents, “emotional support and provision of information from the family’s support group “, “provision of knowledge, skill and information from health care provider “, “communication with health care provider “, “development of social service and welfare facility “.Conclusions:As following, this study provides specific concepts that include the social and cultural background. “emotional support and provision of information from the family’s support group “means: They know the fact that brain tumor causes to die. So that they wanted to know how it is going to die from family caregivers’ view. Also because it is a rare disease, people can not understand their burden of care without experience. So it is necessary opportunities for them to share their experiences. “development of social service and welfare facility “means: This disease is outside the framework of the social service. Despite of having same symptoms as the other diseases, the social support does not target brain tumor’s situation. The needs are complex not only the decrease of burden of patients’ care is needed, but also emotional support, share the experience of patients’ care, development of social service and welfare facility. It is essential to cooperate with health care providers as well as relevant departments.
Exploration of the heterogeneity of moderately emetogenic chemotherapy on response to fosaprepitant in a randomized phase 3 trial
Authors: C. Weinstein, K. Jordan, S. Green, E. Camacho, S. Khanani, E. Beckford-Brathwaite, W. Vallejos, L.W. Liang, S.J. Noga, B.L. Rapoport
Journal: Annals of Oncology (2016)
P08.27 The role of supramarginal resection for single large brain metastases: feasibility, morbidity and local control evaluation
Authors: F. Pessina, P. Navarria, A. Ascolese, L. Cozzi, S. Tomatis, M. Riva, M. Rossi, M. Scorsetti, L. Bello
Journal: Neuro-Oncology (2016)

retrospective analysis of treatment plans to assess the volume of SVZ irradiated using radical radiotherapy treatment.METHODS: The T1-weighted contrast MRI scans of 100 consecutive Glioblastoma patients that had undergone maximal resection, were eligible for radical radiotherapy and chemotherapy were analysed.All patients were treated using IMRT (Intensity-modulated radiation therapy) delivered by the TomoTherapy system.The minimum distance between the gadolinium enhanced tumour resection cavity to the ipsilateral SVZ (which was defined as 5mm lateral to the lateral wall of the lateral ventricle) was measured.In a separate series of 22 patients, the overlap volume between the SVZ and the PTV (planning target volume) was measured.The PTV was generated by growing the GTV (gross tumour volume) isotropically by 30mm.RESULTS: In the analysis of 100 Glioblastoma patients to determine if the SVZ overlapped with the PTV of the tumour, 97% of the patients received some incidental irradiation of their SVZ because it was included within the PTV.This relationship was observed regardless of tumour location.Volume analysis of the 22 patients showed that on average 33.5 % (8.5%-87.1%) of the patients' SVZ was irradiated.CONCLUSIONS: Wide margins used in the treatment planning of Glioblastoma result in a high dose volume that almost always covers the SVZ adjacent to the tumour.However, if the entire ipsilateral SVZ is at risk of harbouring microscopic tumour residuum, it is not routinely covered by the high dose volume using conventional treatment planning protocols.Given that this potential cancer stem cell niche may represent a therapeutically beneficially target, we have shown that there would be utility in a study that treated the entire ipsilateral SVZ within the high dose volume.P08.
Outcome of Transplantation for Acute Leukemia in Down Syndrome
Authors: Johann K. Hitzler, Wensheng He, John J Doyle, Menachem Bitan, Mitchell S. Cairo, Bruce Camitta, Ka Wah Chan, Miguel Angel Diaz, Christopher Fraser, Thomas Gross, John T. Horan, Kimberly A. Kasow, Alana Kennedy-Nasser, Carrie Kitko, Joanne Kurtzberg, Leslie E. Lehmann, David Mitchell, Tracey O'Brien, Michael A. Pulsipher, Franklin O. Smith, Lolie C. Yu, Mei-Jie Zhang, Mary Eapen, Paul A. Carpenter
Journal: Blood (2012)
Tumor-Initiating Cells: a criTICal review of isolation approaches and new challenges in targeting strategies
Authors: Komal Qureshi-Baig, Pit Ullmann, Serge Haan, Elisabeth Letellier
Journal: Molecular Cancer (2017)

Most cancers contain a subpopulation of highly tumorigenic cells, known as cancer stem cells (CSCs) or tumor-initiating cells (TICs). Targeting TICs may be essential to achieve cure, because of their self-renewal and tumorigenic properties as well as their resistance to conventional therapies. Despite significant advances in TIC biology, their isolation and identification remain largely disputed and incompletely established. In this review, we discuss the latest developments in isolation and culturing approaches of TICs, with focus on colorectal cancer (CRC). We feature recent findings on TIC-relevant signaling pathways and the metabolic identity of TICs, as well as their current clinical implications. Lastly, we highlight the influence of inter- and intra-tumoral heterogeneity on TIC function and targeting approaches.
RTHP-14. TREATMENT RESULTS OF STEREOTACTIC RADIOTHERAPY AND BEVACIZUMAB (SRT-Bv) FOR RECURRENT GLIOBLASTOMA
Authors: Takayuki Yasuda, Masayuki Nitta, Takashi Maruyama, Shunsuke Tsuduki, Yoshihiro Muragaki, Takakazu Kawamata
Journal: Neuro-Oncology (2016)

Stereotactic radiotherapy (SRT) has been recently shown to be a meaningful option for recurrent of glioblastoma. However, radiation necrosis is a major problem of the SRT after fractionated radiotherapy for brain tumors. Previous studies have shown that bevacizumab is effective for the radiation necrosis. We evaluated safety of SRT with combination of bevacizumab for patients with recurrent glioblastoma (SRT-Bv group) and compared the clinical results with who treated with bevacizumab alone (Bv group). 19 consecutive patients (median age 43 years; median Karnofsky Performance Status 80) with recurrent glioblastoma after surgical resection of the enhanced lesion followed by fractionated radiotherapy and chemotherapy (ACNU or TMZ) were treated with SRT (Cyberknife) and bevacizumab (10 mg/kg intravenous) every 2 weeks. Median dose of SRT was 42 Gy in 3 to 7 fractionation. We also compared 21 consecutive patients with recurrent glioblastoma treated with bevacizumab in our institute. The median PFS, 6-months PFS and median OS after SRT in the SRT-Bv group was 5.7 month, 37.0 % and 9.6 months, respectively. The median PFS, 6-months PFS and median OS after BV treatment in the Bv group was 3.4 months, 11.0 % and 7.1 months, respectively. There was no significant statistical difference in both PFS (P=0.11) and OS (P=0.08) between two groups. However, there was no in-field recurrence (0/18) in SRT-Bv group and all recurrence was distant or dissemination, suggesting good local control by SRT and bevacizumab treatment. In the SRT group, radiological changes suspected necrosis including appearance of enhanced lesion and enlargement of FLAIR high lesion were observed in 2 patients (11 %) with left temporal tumor. They showed mild aphasia but it was improved with steroid promptly. SRT with bevacizumab is a safe and considerable treatment option for recurrent glioblastoma.
RARE-26. GLIOMATOSIS, TO BE OR NOT TO CEREBRI: AN EVALUATION OF HOST SYSTEMIC IMMUNE FACTORS THAT POTENTIALLY PREDISPOSE TO DIFFUSE INFILTRATIVE GLIOMA PATTERNS
Authors: Na Tosha Gatson, Carlos Kamiya Matsuoka, Yvo Rodriguez-Linares, Clement Pillainayagam, David Cachia, T. Linda Chi, Jeffrey Weinberg, Ivo Tremont-Lukats, Gregory Fuller, John de Groot, Monica Loghin
Journal: Neuro-Oncology (2016)

Gliomatosis cerebri (GC) has been debated as a pathologic entity sui generis versus a simple imaging and histologic pattern. Whereas the World Health Organization (WHO) 2000 classification considered GC a distinct tumor entity, WHO 2007 downgraded GC to a diffuse glioma pattern of extensive CNS infiltration, mostly of astrocytic phenotype involving at least three cerebral lobes, and the WHO 2016 further downgraded GC by removing the chapter. Tumors with distinctive GC presentation have been proven to be molecularly heterogeneous; however, paucity of data defining the pathophysiology and genetic driver(s) of this extensive diffuse infiltration pattern beleaguers the clinicians’ treatment planning. The GC literature is limited to retrospective studies, expert reviews, and one ongoing phase II trial evaluating the use of dose-dense temozolomide. We reviewed 32 primary GC cases (2011-2014) to compare patient demographic, clinical, radiographic, molecular, tissue pathology, and survival data. We found the major histologic phenotype was diffuse astrocytoma WHO grades II–IV (n=28, 87%; grade II, n=10; grade III, n=8; and grade IV, n=10), and noted predominant temporal lobe involvement (n=25, 78%). Treatment varied depending on histologic grade. The overall survival for astrocytic vs oligodendroglial tumors was 11.5 months versus 42 months respectively. Patients with IDH mutation (n=6) fared better, with median survival >33 months, consistent with previous reports. Age, tumor bulk, and other molecular markers did not significantly influence survival. Here, we identified two distinct patient populations, one (n=7, 22%) with a>10-year-prior history of unrelated malignancies, and another (n=10, 31%) with systemic allergy/auto-immune diseases. Interestingly, MRI findings in both groups revealed a posterior cerebral predilection for disease. The clinical challenge to treat patients with extensive, diffuse infiltration of molecularly-diverse gliomas is as yet unmet. Uncovering the drivers of this condition might come with a deeper understanding of patient genetic and tumor microenvironmental predispositions toward the GC infiltrating pattern.
Association of the 1580 (C/T) Polymorphism in the Surfactant Protein B Gene with the Severity of Respiratory Failure after Allogeneic Transplantation.
Authors: Thomas Illmer, Catrin Theuser, Christian Thiede, Markus Schaich, Simone Trautmann, Gert Hoeffken, Gerhard Ehninger, Martin Bornhaeuser
Journal: Blood (2004)
Parathyroid Adenoma Mimicking a Malignant Lymph Node on 18F-Choline PET-CT
Authors: Bliede Van den Broeck, Daan De Maeseneer, Ruth De Gersem, Kathia De Man
Journal: Clinical Nuclear Medicine (2017)

Prostate carcinoma is the most common cancer in men. After local therapy, disease recurs in many patients. A choline PET/CT is indicated in case of biochemical relapse of prostate carcinoma to determine the site of recurrence (local and/or distant) and to help select the next line of therapy. Choline PET-CT is also known to show an elevated uptake in hyperfunctioning parathyroid adenoma. This case report shows the difficulty to distinguish between both entities if they occur simultaneously in an oncologic patient.
Novel Evidence That Pituitary Gonadotropins Directly Stimulate Human Leukemic cells—studies on Myeloid Cell Lines and Primary Patient AML and CML Cells
Authors: Ahmed Ismail, Katarzyna Anna Mierzejewska, Anna Janowska-Wieczorek, A. Robert Turner, Mariusz Z Ratajczak, Magdalena Kucia
Journal: Blood (2014)
MRx102, a Novel Triptolide Analogue, Has Low Nanomolar Activity Against AML Stem/Progenitor Cells in Vitro and in a Murine Model of AML
Authors: Bing Z Carter, Duncan H Mak, Yuxie Shi, John M. Fidler, Rong Chen, Xiaoyang Ling, William Plunkett, Michael Andreeff
Journal: Blood (2011)
Clinical Characteristics and Outcome of 41 Patients with Upper GI Diffuse B-Cell Non-Hodgkin Lymphoma. Results of Brazilian-Italy Lymphoma Registry
Authors: Marcia T Delamain, Eliana C M Miranda, Merli Francesco, Carlos S Chiattone, Anna Fedina, Stefano Luminari, Carmino Antonio De Souza, Federico Massimo
Journal: Blood (2014)
Incidental 99mTc-DTPA Uptake in Tarlov Cysts on Radionuclide SPECT/CT Cisternography
Authors: Shankar Vamadevan, Ken Le, Chuong Bui, Robert Mansberg
Journal: Clinical Nuclear Medicine (2017)

Sacral perineural cysts are also known as Tarlov cysts. A 58-year-old man with suspected intracranial hypotension was evaluated with Tc-DTPA radionuclide cisternography. Radionuclide planar and SPECT/CT cisternography revealed Tc-DTPA uptake in sacral lesions. Spine MRI confirmed Tarlov cysts at the S1 and S2 levels.
NIMG-72. CHANGES IN ACUTE FDG-PET FOLLOWING BEVACIZUMAB ADMINISTRATION IN GLIOBLASTOMA
Authors: Zachary Corbin, Greg Zaharchuk
Journal: Neuro-Oncology (2016)

Bevacizumab (BEV) is an anti-vascular endothelial growth factor (VEGF) antibody approved in recurrent glioblastoma (GBM) whose actions are considered primarily anti-angiogenic. Thus, there has been little interest in studying early effects of BEV with PET imaging. We hypothesize that BEV mediates hyperacute metabolic effects in the tumor field at recurrence and obtained a series of fluorodeoxyglucose (FDG)-PET/MRI studies on GBM patients in the immediate intervals surrounding BEV infusion. Two patients with GBM requiring BEV, one with presumed tumor progression and the other with suspected radiation necrosis, were enrolled in a PET/MRI pilot study after obtaining informed consent. FDG-PET/MRIs of the brain were performed: 1) at baseline – 2-3 days before BEV infusion; 2) hyperacutely – 1 day after infusion; and 3) acutely – 7-8 days after infusion. In the patient with tumor progression, FDG-PET showed a comparatively stable mean lesion SUV, measuring 6.9 (SD=1.6) at baseline, 5.1 (SD=1.4) hyperacutely after BEV infusion, and 6.3 (SD=2.5) acutely after infusion. In contrast, for the patient with treatment effect, the mean lesion SUV from FDG-PET dropped precipitously from 4.6 (SD=1.1) at baseline, to 3.1 (SD=1.0) hyperacutely after BEV infusion, and then to 2.1 (SD=1.3) acutely after infusion. Although further studies are ongoing, the marked difference in SUV attenuation seen in the patient with suspected radiation necrosis suggests differential effects from bevacizumab on the FDG-PET results between the two pathophysiologic entities.
RARE-08. CLINICAL RADIOLOGICAL AND NEUROPATHOLOGIC FINDINGS OF POSTERIOR FOSSA GANGLIOGLIOMAS IN CHILDHOOD
Authors: Thomas Geller, Miguel Guzman
Journal: Neuro-Oncology (2016)

Gangliogliomas are relatively common tumors in adolescent and adult patients with persistent epilepsy and tend to occur in the temporal lobe most frequently. (70%) We have encountered this tumor located in the posterior fossa frequently in our pediatric population, presenting quite differently. We performed a retrospective institutional review of all pediatric gangliogliomas identified from our neuropathology cases files presenting in the interval from 1/2012 through 6/2016. There were five supratentorial ganglioglioma presentations with complex partial seizures or apparent complicated migraines in the population reviewed. There were five infratentorial brainstem, craniocervical junction or cerebellar tumors presenting with bulbar symptoms and/or signs, failure to thrive/growth issues, persistent head tilt, vertigo or obstructive CSF pathway symptoms and findings. One patient with Lhermitte-Duclos features presented with autism and developmental incoordination. The posterior fossa presentations were more likely to involve corticospinal tract features, while cervico-medullary lesions were associated with or upper extremity weakness and hypotonia suggestive of lower motor localized findings. Seizure control in the supratentorial cases was generally successful. Pathological study indicated few cases of BRAF mutation without a clear correlation with poor clinical outcome. Gangliogliomas of the infratentorial space and brainstem in pediatrics are not uncommon and may present with findings more typical of localized mass effect or infiltration of the brainstem, rather than with an epileptic process. This should be considered in the differential diagnosis of an exophytic brainstem lesion.
TNF-α Hypersensitivity of Fanconi Anemia Type C Deficient Cells Is Dependent on the Apoptosis Signal-Regulating Kinase 1 Signaling Pathway.
Authors: Laura S. Haneline, Khadijeh R. Bijangi-Vishehsaraei, Adam Werne, Kristina Wilson McKenzie, Susanna Davis, Hidenori Ichijo, Mohammad R. Saadatzadeh
Journal: Blood (2004)
Carma1 Is Important for T-ALL CNS Infiltration and Survival in an Animal Model of T-ALL
Authors: Sreenivasa Rao Oruganti, Christina Halsey, Savannah Krebsbach, Francois Asperti-Boursin, Sumit Patel, Ksenia Matlawska-Wasowska, Stuart S. Winter, Judy Cannon
Journal: Blood (2014)
A Correction to the Research Article Titled: "Human Neural Stem Cells Induce Functional Myelination in Mice with Severe Dysmyelination" by N. Uchida, K. Chen, M. Dohse, K. D. Hansen, J. Dean, J. R. Buser, A. Riddle, D. J. Beardsley, Y. Wan, X. Gong, T. Nguyen, B. J. Cummings, A. J. Anderson, S. J. Tamaki, A. Tsukamoto, I. L. Weissman, S. G. Matsumoto, L. S. Sherman, C. D. Kroenke, S. A. Back
Journal: Science Translational Medicine (2012)
Once Daily IV Busulfan Given with Fludarabine in Allogeneic Stem Cell Transplantation Conditioning: High vs Low Busulfan AUC Does Not Alter Toxicities or Transplant Outcome.
Authors: Michelle Geddes, Shabal B. Kangarloo, Farrukh Naveed, Ahsan M. Chaudhry, Oluyemi Jeje, Mary L. Savoie, Nizar J. Bahlis, Douglas A. Stewart, Christopher Brown, Jan Storek, Diana Quinlan, Borje Andersson, James A. Russell
Journal: Blood (2005)